Pyxis Oncology Inc (PYXS) Stock Price, Quote & News

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 453 3596

Website: www.pyxisoncology.com

Address:

321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States

banderkoeta Aug. 20 at 1:51 PM

$PYXS turd is holding strong bear market a week now. Pump feeling

1 · Reply

Mustang8 Aug. 20 at 12:43 AM

$PYXS Lots of upcoming events let’s see

1 · Reply

JacksofAmerica Aug. 19 at 10:31 PM

$PYXS just bought back in at $1.20 lets see some movement 👀

1 · Reply

banderkoeta Aug. 19 at 12:54 PM

$PYXS all rating r high still dropt atl nd no movement of vol

0 · Reply

JarvisFlow Aug. 19 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Pyxis Oncology ( $PYXS ), setting the rating to Buy with a target price of 5.

0 · Reply

biohuntress Aug. 19 at 11:37 AM

$PYXS https://www.gurufocus.com/news/3068576/hc-wainwright-maintains-buy-rating-for-pyxis-oncology-pyxs-at-500-pyxs-stock-news

0 · Reply

d_risk Aug. 17 at 4:38 PM

$PYXS - Pyxis Oncology Inc. Common Stock - 10Q - Updated Risk Factors PYXS’s latest 10-Q risk factors spotlight expanded funding and cash runway uncertainties, exclusive dependence on micvotabart pelidotin, heightened clinical and regulatory hurdles, new product liability and international risks, trimmed general warnings, and added detail on IP, manufacturing, and litigation exposures, with several prior risk disclosures removed or condensed. #Biotechnology #IntellectualProperty #FundingUncertainty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/PYXS/10-Q/2025-08-14

0 · Reply

biohuntress Aug. 14 at 8:12 PM

$PYXS https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-reports-second-quarter-2025-financial-results-and

2 · Reply

zackopaw Aug. 14 at 6:30 PM

$PYXS started new position with 9.5k shares at 1.10. Also long at $BDTX

0 · Reply

Rohtan Aug. 14 at 2:50 PM

$PYXS I am fully loaded here. Can’t wait to see this Soar

0 · Reply

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 4:30 PM EDT - 7 weeks ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2025, 7:00 AM EDT - 3 months ago

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 7:30 AM EDT - 3 months ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Apr 25, 2025, 1:17 PM EDT - 4 months ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 2, 2025, 7:30 AM EDT - 5 months ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 4:30 PM EDT - 5 months ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 18, 2025, 7:30 AM EDT - 5 months ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:30 AM EST - 6 months ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:30 AM EST - 6 months ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 4, 2025, 7:30 AM EST - 7 months ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Dec 19, 2024, 4:08 PM EST - 8 months ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Dec 7, 2024, 1:30 AM EST - 9 months ago

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Nov 21, 2024, 9:18 AM EST - 9 months ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Nov 20, 2024, 4:05 PM EST - 9 months ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 8, 2024, 1:30 PM EST - 10 months ago

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Sep 13, 2024, 7:08 AM EDT - 1 year ago

Moment Of Truth Approaches For Pyxis Oncology

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

May 30, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 9, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 21, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 7, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 5, 2024, 4:45 PM EST - 1 year ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Nov 7, 2023, 4:30 PM EST - 1 year ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Sep 27, 2023, 9:18 AM EDT - 2 years ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Sep 7, 2023, 8:09 AM EDT - 2 years ago

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Aug 31, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 23, 2023, 8:35 AM EDT - 2 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 10, 2023, 2:56 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Jul 10, 2023, 3:01 AM EDT - 2 years ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Jun 15, 2023, 8:20 AM EDT - 2 years ago

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Jun 12, 2023, 2:59 AM EDT - 2 years ago

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

May 30, 2023, 10:52 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

May 30, 2023, 8:30 AM EDT - 2 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 24, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology to Acquire Apexigen

May 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

Mar 27, 2023, 7:32 AM EDT - 2 years ago

Pyxis Oncology: Cashed Up And Entering The Clinic

Mar 22, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Mar 16, 2023, 7:30 AM EDT - 2 years ago

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

Feb 13, 2023, 8:00 AM EST - 2 years ago

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

Dec 1, 2022, 6:45 AM EST - 2 years ago

Pyxis Oncology Announces FDA Clearance of Two IND Applications

banderkoeta Aug. 20 at 1:51 PM

$PYXS turd is holding strong bear market a week now. Pump feeling

1 · Reply

Mustang8 Aug. 20 at 12:43 AM

$PYXS Lots of upcoming events let’s see

1 · Reply

JacksofAmerica Aug. 19 at 10:31 PM

$PYXS just bought back in at $1.20 lets see some movement 👀

1 · Reply

banderkoeta Aug. 19 at 12:54 PM

$PYXS all rating r high still dropt atl nd no movement of vol

0 · Reply

JarvisFlow Aug. 19 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Pyxis Oncology ( $PYXS ), setting the rating to Buy with a target price of 5.

0 · Reply

biohuntress Aug. 19 at 11:37 AM

$PYXS https://www.gurufocus.com/news/3068576/hc-wainwright-maintains-buy-rating-for-pyxis-oncology-pyxs-at-500-pyxs-stock-news

0 · Reply

d_risk Aug. 17 at 4:38 PM

0 · Reply

biohuntress Aug. 14 at 8:12 PM

$PYXS https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-reports-second-quarter-2025-financial-results-and

2 · Reply

zackopaw Aug. 14 at 6:30 PM

$PYXS started new position with 9.5k shares at 1.10. Also long at $BDTX

0 · Reply

Rohtan Aug. 14 at 2:50 PM

$PYXS I am fully loaded here. Can’t wait to see this Soar

0 · Reply

Tacto Aug. 14 at 2:34 AM

$PYXS Stochastic Oversold Reversal today, as shown in the lower part of the attached picture, where it crossed above the 20% mark

1 · Reply

Tacto Aug. 14 at 2:17 AM

$PYXS The official FDA record for Study of PYX-201 (MICVO) in Solid Tumors (NCT05720117) was updated exactly two weeks ago. Estimated enrollment was nearly tripled, from 120 to 330, which is certainly very interesting, to say the least. Also, Madrid and London locations were added to the clinical study Here's the link to the side-by-side comparison between the latest update and the one prior - https://clinicaltrials.gov/study/NCT05720117?term=pyxis&rank=3&tab=history&a=18&b=19&compareMode=sideBySide#version-content-panel

0 · Reply

banderkoeta Aug. 13 at 1:40 PM

$PYXS this is dead one more week then im gone

2 · Reply

garygb Aug. 11 at 6:58 PM

$PYXS I'm in.

1 · Reply

biohuntress Aug. 11 at 5:11 PM

$PYXS Cantor Global Healthcare Conference 2025 Sep 3 - Sep 5, 2025 H.C. Wainwright 27th Annual Global Investment Conference Sep 8, 2025 at 10:30 AM EDT

0 · Reply

Rohtan Aug. 11 at 4:04 PM

$PYXS added 7k more here

3 · Reply

banderkoeta Aug. 7 at 12:11 PM

$PYXS $XFOR why

4 · Reply

Rohtan Aug. 7 at 1:06 AM

$PYXS $XFOR my main holdings. I am very bullish on these 2 stocks for next few months

0 · Reply

Rohtan Aug. 7 at 1:04 AM

$PYXS bought more. Now own 9k . I am very bullish on this one.

1 · Reply

Bullbear1010101 Aug. 6 at 11:40 PM

$PYXS 1.05 now people!?

0 · Reply

Bullbear1010101 Jul. 31 at 10:14 PM

$PYXS looks busted. people bailing it seems. almost lowest in 2months

1 · Reply

fuerst73 Jul. 29 at 1:26 PM

$PYXS — Something’s lining up here. Big volume spike on June 27th caught my eye, and since July 11th my indicator has been quietly printing those first green bars — signaling early accumulation. Now trading above the 200MA (4H), and volume’s starting to return. Interesting setup, definitely going on my watchlist. Let’s see if this one breaks out.

1 · Reply

Market Cap	74.34M
Revenue (ttm)	16.15M
Net Income (ttm)	-77.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-478.82%
Debt to Equity Ratio	0.00

Volume	224,100
Avg Vol	514,632
Day's Range	N/A - N/A
Shares Out	61.95M
Stochastic %K	68%
Beta	1.13
Analysts	Strong Sell
Price Target	$6.20